Sun, Nov 23, 2014, 4:39 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

The Blackstone Group L.P. Message Board

mecosmo2 109 posts  |  Last Activity: Nov 22, 2014 3:16 PM Member since: May 19, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • With its traditionally 80 percent–accurate weather forecasts, The Old Farmer’s Almanac predicts that this winter will be another arctic blast with above-normal snowfall throughout much of the nation. The extreme weather will continue into Summer 2015, which is expected to be predominantly hot and dry.
    all together the weather should increase revenue!

    Sentiment: Buy

  • Aspire capital filed a Form 13-G this afternoon (link a above and section pasted below) reporting Apricus holdings of 2,296,500 shares, an amount that is about 0.4M shares in excess of the share ownership of approximate 1.9M shares that could be derived from APRI's filings concerning the equity line. $19.1M remains available under that line.

    Sentiment: Strong Buy

  • Roth Capital analyst Scott Henry reiterated a Buy rating on Apricus Biosciences (NASDAQ:APRI) with a $4 price target, following the company’s third quarter results, which were within expectations.
    Henry noted, “APRI reported revenues of $1.9 million (versus our target of $1.2 million). The upside was from milestones ($500K) and manufacturing revenues ($398K). There were no Vitaros royalties in the quarter. The higher revenue upside reduced the EPS loss by ~$0.01. Lower spending further reduced the EPS loss by another ~$0.01 and the reported EPS loss of $0.08 was modestly smaller than our targeted loss of $0.10. Fundamentally, we viewed the quarter in-line. The company has cash of $16.1 million, which combined with funding options, should provide cash “through 2015″.”
    The analyst added, “The Vitaros launch is progressing in Europe with potential revenue inflection points in 2015. The pipeline could also provide 2015 catalysts with clinical data targeted for both RayVa and Fispemifene.”

    Sentiment: Strong Buy

  • Males over 25 aprox 22 million Looks like a good market and launch comming up!!

    Sentiment: Buy

  • http://seekingalpha.com/article/2690455-atlantic-powers-results-dont-look-terrible-to-me?ifp=0

    Finally, if we adjust for the amount of premium paid to redeem two series of notes in Q1 2014, we come up with a number that should best represent the operational performance of AT. We must adjust this because the one-time premium paid to redeem the notes is also booked to interest expenses and does not represent the actual interest incurred for the period. Although I will probably be faced with extreme criticisms for saying so, it appears that AT hasn't done too poorly operationally and we have even seen a small improvement year over year.

    Sentiment: Buy

  • •Atlantic Power (NYSE:AT) declares C$0.03/share quarterly dividend.
    •Forward yield 5.74%
    •Payable Dec. 31; for shareholders of record Nov. 28; ex-div Nov. 25.

    Sentiment: Buy

  • Reply to

    AT - article

    by jmesa Nov 12, 2014 8:16 AM
    mecosmo2 mecosmo2 Nov 12, 2014 12:00 PM Flag

    It appears that some analyst have their own agenda , and some are dump and pump its all about making MONEY! Yes we all know that AT has a very poor record with past BOD, that is why it has been changed.!!
    This is a long term investment it will take a year at least to get the turn around. With lower cost overall it will be a great investment IMO

    Sentiment: Buy

  • https://www.dropbox.com/s/o5oaj8xa3yv2w4d/Apricus%20Biosciences%20(APRI)%20Initiation%20(Autosaved).pdf?dl=0

    Sentiment: Buy

  • NYSE:AT) was upgraded by analysts at TD Securities from a "reduce" rating to a "hold

    Sentiment: Buy

  • Total revenues were $7.4 million for the nine-month period ended September 30, 2014, compared to total revenue of $2.1 million for the nine month period ended September 30, 2013. For the nine-month period ended September 30, 2014, net loss was $4.5 million or $(0.12) per share compared to a net loss of $15.6 million or $(0.47) per share for the nine-month period ended September 30, 2013.

    Sentiment: Buy

  • Longer-term goal of successfully pursuing value-enhancing acquisition, development or joint venture opportunities
    Recent Financial and Operational Accomplishments
    Completed major optimization projects planned for this year and expect to realize annual run-rate cash flow benefit of at least $8 million in 2015, at least half of which has been realized this year
    Implemented personnel reductions and took other steps consistent with G&A savings target for 2015
    Reduced outstanding amount of APLP term loan through mandatory amortization and cash sweep and amortized project debt by $73 million year to date; on track to achieve approximate $85 million reduction by year-end 2014
    Apricus continues to receive multiple commercial product orders of Vitaros from its partners, and is currently manufacturing multiple product batches through its contract manufacturer in Canada to support launches in Europe. The commercialization of the product has been fully licensed to these partners, with Apricus positioned to earn tiered double-digit royalties and more than $200 million in potential milestone payments.

    Sentiment: Buy

  • •Longer-term goal of successfully pursuing value-enhancing acquisition, development or joint venture opportunities

    Recent Financial and Operational Accomplishments
    •Completed major optimization projects planned for this year and expect to realize annual run-rate cash flow benefit of at least $8 million in 2015, at least half of which has been realized this year
    •Implemented personnel reductions and took other steps consistent with G&A savings target for 2015
    •Reduced outstanding amount of APLP term loan through mandatory amortization and cash sweep and amortized project debt by $73 million year to date; on track to achieve approximate $85 million reduction by year-end 2014

    Sentiment: Buy

  • Our results year to date have been driven by strong wind generation, increased waste heat at our Ontario projects, and lower maintenance and administrative expenses. We are encouraged by the progress we have made in improving the performance of our projects and reducing our costs, which we expect will benefit future periods. We also maintained a strong liquidity position of $272 million, including $168 million of unrestricted cash," said Kenneth Hartwick, interim President and CEO of Atlantic Power. "Although our availability improved this quarter, we had lower dispatch at a few projects primarily due to a mild summer. Notwithstanding that, we still expect 2014 Project Adjusted EBITDA to be in the middle of our initial guidance range. During the quarter, we incurred severance costs associated with recent management changes and steps to reduce our cost structure. These costs will reduce Free Cash Flow, and thus we now expect our Free Cash Flow to be in the lower end of our initial guidance range."

    Sentiment: Buy

  • https://www.youtube.com/watch?v=KVdJ5AdmhSQ

    Sentiment: Strong Buy

  • here comes the GIRLS and don't underestimate them!
    Men outscore women 26 to zero when it comes to FDA-approved treatments marketed for Sexual Dysfunction.
    1 in 10 women
    suffer from sexual dysfunction with distress
    43% of women suffer
    from sexual dysfunction, while 31% of men suffer the same
    How to Even the Score
    Even the Score: A campaign for women’s sexual health equity is leading the fight for safe, FDA-approved treatment options for women's sexual dysfunction, and for the rights of women to be given the same access to treatments that allows them to make decisions on their sexual health with their providers.
    We have waited long enough. It's time for the FDA to act, with our support, for women by approving the first-ever drug to treat the most common form of women's sexual dysfunction and open the field of research for a variety of treatment options to come.
    Join in and sign the petition

    Sentiment: Strong Buy

  • https://www.yahoo.com/health/the-fda-is-finally-paying-attention-to-female-sexual-101179490712.html

    Sentiment: Strong Buy

  • Agreed, that Cantor Fitzgerald has never carried any weight with the street so as you said their hold could mean BUY since their BUY was a hold previously!

    Sentiment: Strong Buy

  • Apricus Biosciences (NASDAQ:APRI) Director Sandford D. Smith acquired 26,500 shares of the company’s stock on the open market in a transaction dated Thursday, October 23rd. The stock was purchased at an average price of $1.57 per share, for a total transaction of $41,605.00. Following the completion of the purchase, the director now directly owns 26,500 shares in the company, valued at approximately $41,605. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

    Shares of Apricus Biosciences (NASDAQ:APRI) opened at 1.61 on Tuesday. Apricus Biosciences has a 52 week low of $1.12 and a 52 week high of $2.71. The stock has a 50-day moving average of $1.56 and a 200-day moving average of $1.97. The company’s market cap is $61.3 million.

    Apricus Biosciences (NASDAQ:APRI) last issued its quarterly earnings data on Tuesday, August 12th. The company reported $0.05 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.04) by $0.09. The company had revenue of $5.50 million for the quarter, compared to the consensus estimate of $5.45 million. On average, analysts predict that Apricus Biosciences will post $-0.22 earnings per share for the current fiscal year

    Sentiment: Strong Buy

  • preventing shares from being short - in particular from what is often seen in penny stock manipulation. I've heard that there are three measures that could be taken but wanted to see if there was any truth to them or if there were perhaps other possibilities? What I've heard is as follows:

    1) Place a Good till cancel sell on your long position at a higher price
    2) Ask your broker to issue a certificate to you
    3) Have your trades done in a cash account as suppose to a margin account

    Answer YES on 1 and 3 ONE is the easy way!!

    Sentiment: Buy

  • mecosmo2 mecosmo2 Oct 26, 2014 11:31 AM Flag

    androxyl is approved and available on line, or do you mean ANDROXY WHICH IS ALSO APPROVED?.

    Sentiment: Buy

BX
33.12+0.26(+0.79%)Nov 21 4:02 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.